Adaptive Biotechnologies Corp (ADPT)vsNovartis AG ADR (NVS)
ADPT
Adaptive Biotechnologies Corp
$24.20
-0.12%
HEALTHCARE · Cap: $3.90B
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 18302% more annual revenue ($56.69B vs $308.08M). NVS leads profitability with a 22.5% profit margin vs -20.7%. NVS earns a higher WallStSmart Score of 51/100 (C-).
ADPT
Avoid28
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+51.0%
Fair Value
$31.91
Current Price
$24.20
$7.71 discount
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 21.5% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
Trading at 26.9x book value
ROE of -23.0% — below average capital efficiency
Negative free cash flow — burning cash
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ADPT
The strongest argument for ADPT centers on Revenue Growth. Revenue growth of 21.5% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : ADPT
The primary concerns for ADPT are EPS Growth, Price/Book, Return on Equity. Debt-to-equity of 2.87 is elevated, increasing financial risk.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
ADPT profiles as a growth stock while NVS is a value play — different risk/reward profiles.
ADPT carries more volatility with a beta of 2.10 — expect wider price swings.
ADPT is growing revenue faster at 21.5% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 28/100), backed by strong 22.5% margins. ADPT offers better value entry with a 51.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adaptive Biotechnologies Corp
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?